May 4, 2011 | Biodesix has announced the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute. The study collects biospecimens and data from lung cancer patients in order to facilitate and accelerate the development and delivery of diagnostic tests and treatments tailored to the individual patient. As part of the study, Biodesix is performing VeriStrat testing on eligible patients and serving as ALCMI's biorepository for all serum samples collected from the CASTLE study subjects for future research. Biodesix